Incyte News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

11.11.20	Xencor, MorphoSys And Incyte Ink Collaboration Deal (RTTNews)
05.11.20	Incyte Q3 Adj. Earnings, Revenue Miss Estimates - Quick Facts (RTTNews)
30.10.20	Lilly, Incyte Report Positive New Data For Baricitinib In Adult Patients With Alopecia Areata (RTTNews)
29.10.20	Incyte's Atopic Dermatitis Studies Of Ruxolitinib Cream Show Clinically Meaningful Improvements (RTTNews)
18.09.20	Lilly, Incyte: CHMP Adopts Positive Opinion For Baricitinib In Treatment Of Atopic Dermatitis (RTTNews)
14.09.20	Lilly, Incyte Announce Initial Data From Adaptive COVID-19 Treatment Trial - Quick Facts (RTTNews)
04.08.20	Incyte Q2 Profit Tops Estimates - Quick Facts (RTTNews)
04.08.20	Incyte Corporation Q2 adjusted earnings Beat Estimates (RTTNews)
29.06.20	Incyte Receives Approval For Tabrecta In Japan For Patients With Advanced NSCLC With METex14 (RTTNews)
15.06.20	Lilly Starts Phase 3 Clinical Trial With Baricitinib For Hospitalized COVID-19 Patients (RTTNews)
21.05.20	MorphoSys Announce Validation Of EMA Application For Tafasitamab (RTTNews)
14.05.20	MorphoSys : Long-term Data From L-MIND Study Confirms Primary Analysis Results (RTTNews)
05.05.20	Incyte Slips To Loss In Q1, Despite Higher Revenues - Quick Facts (RTTNews)
20.04.20	FDA Approves First Targeted Treatment For Bile Duct Cancer (RTTNews)
04.03.20	MorphoSys, Incyte Receive Antitrust Clearance For Collaboration On Tafasitamab (RTTNews)
13.02.20	Incyte Q4 Adj. Operating Income Rises; Jakafi Revenues Up 23% - Quick Facts (RTTNews)
13.02.20	Incyte Corporation Q4 adjusted earnings of $0.65 per share (RTTNews)
12.02.20	Lilly's Study Meets Primary Endpoint Of 75% Improvement Of Skin Inflammation (RTTNews)
30.01.20	Eli Lilly, Incyte: Baricitinib Meets Primary Endpoint In BREEZE-AD5 Study (RTTNews)
27.01.20	Lilly : Study Meets Primary Endpoint Of 75% Improvement Of Skin Inflammation (RTTNews)
13.01.20	MorphoSys, Incyte Agree To Co-commercialize Tafasitamab In The U.S. (RTTNews)
03.01.20	DRRX Plunges On Psoriasis Trial Data, INCY Fails GRAVITAS-301 Test, AGRX Abuzz (RTTNews)
14.12.19	Are These Biotech Companies Buyout Candidates? Deal Or No Deal? (RTTNews)
29.10.19	Incyte Q3 Profit Surges; Raises FY19 Jakafi Revenue Outlook - Quick Facts (RTTNews)
30.07.19	Incyte Corporation Q2 adjusted earnings Beat Estimates (RTTNews)
30.04.19	Incyte To No Longer Participate In Co-funding Of Development Of Baricitinib (RTTNews)
30.04.19	Incyte Corporation Q1 adjusted earnings of $0.62 per share (RTTNews)
26.04.19	Biotech Stocks Facing FDA Decision In May 2019 (RTTNews)
21.02.19	Beware Of Fake Leukemia Drug Iclusig, Warns WHO (RTTNews)
04.02.19	Lilly : Baricitinib Meets Primary Endpoint In BREEZE-AD1 And BREEZE-AD2 (RTTNews)
30.01.19	Biotech Stocks Facing FDA Decision In February (RTTNews)
03.01.19	Incyte Names Christiana Stamoulis CFO - Quick Facts (RTTNews)
17.12.18	Innovent, Incyte In Deal For Three Clinical-stage Product Candidates In China (RTTNews)
13.12.18	Eli Lilly : FDA Grants Fast Track Designation To Baricitinib Development Program (RTTNews)
30.10.18	Incyte Corporation Q3 adjusted earnings Miss Estimates (RTTNews)
25.10.18	Incyte: FDA Grants Priority Review For Ruxolitinib (RTTNews)
22.10.18	FDA Extends Date On BMY's SBLA, Genmab Meets Phase 3 Goals, NCNA, LPTX On Watch (RTTNews)
22.10.18	Lilly And Incyte Update Safety Analysis Of OLUMIANT (RTTNews)
21.10.18	Incyte Announces Positive Interim Data From Phase 2 Trial Of Pemigatinib (RTTNews)
09.09.18	Week Ahead In Pharmaceuticals: 5 Stocks To Watch (KNSA, INCY, ANAB...) (RTTNews)
07.09.18	Incyte CFO David Gryska To Retire At 2018- End; Search Underway For New CFO (RTTNews)
21.06.18	Incyte: REACH1 Pivotal Trial With Ruxolitinib Meets Primary Endpoint (RTTNews)
11.06.18	Lilly to Unveil New Data at the Annual European Congress of Rheumatology, Furthering Commitment to Scientific Discovery in Immunology (PR Newswire)
06.06.18	Lifshitz & Miller LLP Announces Investigation of ARMO BioSciences, Inc., Financial Engines, Inc., Globalstar, Inc., Gridsum Holding Inc., InnerWorkings, Inc., Incyte Corporation, PPG Industries, Inc. (PR Newswire)
04.06.18	FDA Nod For LLY/INCY RA Drug, JAZZ Hits Right Tones, SLS' Study Stopped Early (RTTNews)
01.06.18	FDA Approves OLUMIANT® (baricitinib) 2-mg Tablets for the Treatment of Adults with Moderately-to-Severely Active Rheumatoid Arthritis (PR Newswire)
24.04.18	PRTA Jolted, FDA Strikes Down PFE's Herceptin Biosimilar, No Relief Yet For KMDA (RTTNews)
24.04.18	FDA Panel Backs Lower Dose Of Lilly-Incyte Arthritis Drug, But Not Higher Dose (RTTNews)
24.04.18	FDA Advisory Committee Recommends the Approval of Baricitinib 2mg, but not 4mg, for the Treatment of Moderately-to-Severely Active Rheumatoid Arthritis (PR Newswire)
20.04.18	SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Incyte Corporation (INCY) (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

18:01		Gewinne in New York: S&P 500 legt mittags zu
19.11.24		Börse New York in Grün: S&P 500 zum Ende des Dienstagshandels im Aufwind
19.11.24		Optimismus in New York: Anleger lassen S&P 500 am Dienstagnachmittag steigen
19.11.24		Dienstagshandel in New York: S&P 500 mittags mit grünem Vorzeichen
19.11.24		Verluste in New York: S&P 500 startet im Minus
29.10.24		Börse New York in Grün: S&P 500 beendet die Sitzung im Plus
29.10.24		Börse New York: S&P 500 fester
29.10.24		Optimismus in New York: So bewegt sich der S&P 500 am Mittag

18:01

Gewinne in New York: S&P 500 legt mittags zu

19.11.24

Börse New York in Grün: S&P 500 zum Ende des Dienstagshandels im Aufwind

19.11.24

Optimismus in New York: Anleger lassen S&P 500 am Dienstagnachmittag steigen

19.11.24

Dienstagshandel in New York: S&P 500 mittags mit grünem Vorzeichen

19.11.24

Verluste in New York: S&P 500 startet im Minus

29.10.24

Börse New York in Grün: S&P 500 beendet die Sitzung im Plus

29.10.24

Börse New York: S&P 500 fester

29.10.24

Optimismus in New York: So bewegt sich der S&P 500 am Mittag

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Logitech Intl	74.04	2.41 %	K V
ABB	52.12	1.68 %	K V
Geberit	552.80	1.32 %	K V
Alcon	78.04	1.19 %	K V
CieFinRichemont	129.05	1.10 %	K V
Swiss Life Hldg	686.00	-0.64 %	K V
Zurich Insur Gr	555.20	-1.00 %	K V
Holcim	90.66	-1.31 %	K V
Kuehne+Nagel Int	210.60	-1.31 %	K V
Novartis	90.10	-3.14 %	K V

Nachrichten zu Incyte Corp.

Aktien Top/Flop

Incyte Peer Group Nachrichten

Meistgelesene Nachrichten